Demineralized Bone Fiber (DBF™)

Theracell And AlloSource Announce Second Patent For Bone Fiber Technology

Demineralized Bone Fiber (DBF™) patent to expand TheraCell’s osteobiologic patent portfolio Northridge, Cali. and Centennial, Colo. — March 9, 2017 — TheraCell, a regenerative medicine company, today announced it was awarded a second patent for its demineralized bone fiber (DBF™) technology by the United States Patent and Trademark Office. The addition of U.S. Patent Number 9,572,912, titled Demineralized bone fibers having controlled geometry and shapes and methods thereof, expands TheraCell’s intellectual property portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry. TheraCell’s DBF™ technology is incorporated into two innovative demineralized cortical fiber allografts, AlloFuse® Cortical…

TheraCell And AlloSource Announce Issuance Of Patent For Bone Fiber Technology

Northridge, Calif. and Centennial, Colo. — Oct. 25, 2016 — TheraCell, a regenerative medicine company, today announced that the United States Patent and Trademark Office (USPTO) will issue TheraCell a patent for its demineralized bone fiber (DBF™) technology. The addition of this patent expands TheraCell’s patent portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry. TheraCell’s DBF technology is incorporated into two new innovative demineralized cortical fiber allografts, AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats, provided by AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts. AlloFuse Cortical Fibers…